Finance

Lists
TEVA:NYSE
Teva Pharmaceutical Industries Limited
USD 41,72
+1,14%
(+0,47) 1D
14 Okt., 11:31:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TEVA...
Open
USD 41,11
High
USD 41,87
Low
USD 41,11
Mkt. cap
47,83 mjd
Avg. vol.
5,65 m
Volume
2,47 m
52-wk high
USD 42,02
52-wk low
USD 18,82
Beta
1,07
Shares outstanding
1,17 mjd
No. of employees
32 k
Open
USD 41,11
High
USD 41,87
Low
USD 41,11
Mkt. cap
47,83 mjd
Avg. vol.
5,65 m
Volume
2,47 m
52-wk high
USD 42,02
52-wk low
USD 18,82
Beta
1,07
Shares outstanding
1,17 mjd
No. of employees
32 k
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Limited
CEORichard Francis
Employees32 k
Founded13 Feb. 1944
Headquarters-
SectorPharmaceutical industry
Websiteteva.co.il
Analyst ratings
Based on 9 analysts giving stock ratings to TEVA in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for TEVA in the last 3 months.
Highest
Current USD 41,72
USD 50,00 (+19,85%)
Average
USD 44,00 (+5,47%)
Lowest
USD 40,00 (-4,12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Buy
Initiated
USD 45,00
+7,9%
09/09/2026
Ashwani Verma
UBS
Buy
Maintained
USD 48,00
+15,1%
09/04/2026
Dennis Ding
Jefferies
Buy
Maintained
USD 40,00
-4,1%
09/03/2026
Louise Chen
Scotiabank
Buy
Maintained
USD 40,00
-4,1%
09/03/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
USD 50,00
+19,8%
09/02/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
USD 43,00
+3,1%
09/02/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
09/02/2026
David Amsellem
Piper Sandler
Buy
Reiterated
USD 44,00
+5,5%
08/27/2026
Glen Santangelo
Barclays
Buy
Maintained
USD 42,00
+0,7%
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/15/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
USD 50,00
+19,8%
04/30/2026
Les Sulewski
Truist Financial
Buy
Reiterated
USD 45,00
+7,9%
04/30/2026
Last report
29 Jul. 2026
Fiscal period
Q2 2026
USD 0,02 / USD 0,11
-81,46%miss
Revenue / Est. (USD)
4,14 mjd / 4,03 mjd
+2,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
4,48 mjd
4,71 mjd
3,98 mjd
4,14 mjd
Cost of goods sold
2,18 mjd
2,06 mjd
2,01 mjd
1,99 mjd
Cost of revenue
2,18 mjd
2,06 mjd
2,01 mjd
1,99 mjd
Research and development expenses
256,00 m
267,00 m
222,00 m
970,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 m
1,12 mjd
1,00 mjd
1,03 mjd
Operating expense
1,24 mjd
1,37 mjd
1,21 mjd
1,99 mjd
Total operating expenses
3,41 mjd
3,43 mjd
3,22 mjd
3,98 mjd
Operating income
1,07 mjd
1,28 mjd
763,00 m
167,00 m
Other non operating income
-27,00 m
-
-13,00 m
-69,00 m
EBT including unusual items
648,00 m
90,00 m
436,00 m
-455,00 m
EBT excluding unusual items
832,00 m
1,08 mjd
547,00 m
-57,00 m
Income tax expense
214,00 m
-390,00 m
67,00 m
121,00 m
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 m
-17,00 m
-14,00 m
-18,00 m
Net income
433,00 m
480,00 m
369,00 m
-576,00 m
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 m
-
-
Interest expense
-205,00 m
-280,00 m
-191,00 m
-186,00 m
Net interest expenses
-205,00 m
-188,00 m
-191,00 m
-186,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 mjd
1,54 mjd
1,00 mjd
408,00 m
Gain or loss from assets sale
-
-
-8,00 m
-12,00 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme